Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma

Antonio Gasbarrini, Francesca Romana Ponziani, Sherrie Bhoori, Alessandro Germini, Marco Bongini, Maria Flores, Carlo Sposito, Antonio Facciorusso, Vincenzo Mazzaferro

Risultato della ricerca: Contributo in rivistaArticolo in rivista

15 Citazioni (Scopus)

Abstract

Various grades of adverse events are associated with sorafenib and have recently been considered as a surrogate of response in patients with advanced hepatocellular carcinoma. The aim of this prospective study was to measure the efficacy of a sorafenib dose reduction regimen, adjusted on patient's tolerability, and aimed at increasing the exposure to the drug.
Lingua originaleEnglish
pagine (da-a)N/A-N/A
RivistaLiver International
DOI
Stato di pubblicazionePubblicato - 2015

Keywords

  • adverse events
  • hepatocellular carcinoma
  • sorafenib
  • tolerable adverse events protocol
  • toxicity
  • tumor response

Fingerprint Entra nei temi di ricerca di 'Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma'. Insieme formano una fingerprint unica.

Cita questo